Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
15.89(c) 15.9(c) 16.19(c) 15.84(c) 15.68(c) Last
1 527 688 2 395 261 2 553 863 2 047 754 2 950 425 Volume
-2.40% +0.06% +1.82% -2.16% -1.01% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 612 M - -
Net income 2022 295 M - -
Net cash position 2022 1 127 M - -
P/E ratio 2022 17,6x
Yield 2022 -
Sales 2023 1 848 M - -
Net income 2023 339 M - -
Net cash position 2023 1 317 M - -
P/E ratio 2023 14,9x
Yield 2023 -
Capitalization 5 046 M 5 046 M -
EV / Sales 2022 2,43x
EV / Sales 2023 2,02x
Nbr of Employees 954
Free-Float 97,8%
More Financials
Company
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with... 
More about the company
Ratings of Exelixis, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXELIXIS, INC.
09/15Transcript : Exelixis, Inc. Presents at BofA Securities Global Healthcare Con..
CI
09/13Transcript : Exelixis, Inc. Presents at Morgan Stanley 20th Annual Global Hea..
CI
09/12Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluatin..
AQ
09/10Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluatin..
BU
09/10Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Eva..
CI
09/07Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients w..
BU
09/07Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Pati..
CI
09/06Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
BU
09/02Exelixis Seeks to Block Generic Version of Kidney Cancer Drug
MT
09/02Exelixis, Inc. : Other Events (form 8-K)
AQ
08/25Bioinvent International Ab : Interim report January-June 2022
AQ
08/09Exelixis : Q2 2022 Earnings Slides With Appendix
PU
08/09Transcript : Exelixis, Inc., Q2 2022 Earnings Call, Aug 09, 2022
CI
08/09Exelixis : Q2 Earnings Snapshot
AQ
08/09Exelixis : ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE -..
PU
More news
News in other languages on EXELIXIS, INC.
09/10Exelixis, Inc. Annonce à l'ESMO 2022 des résultats de l'escalade de dose de l'essai de ..
09/07Exelixis, Inc. Annonce des résultats détaillés de l'essai pivot de phase 3 COSMIC-313 c..
08/09Exelixis annonce un bénéfice ajusté plus faible au deuxième trimestre et maintient ses ..
08/09Earnings Flash (EXEL) EXELIXIS affiche un chiffre d'affaires de 419,4 millions de dolla..
08/09Exelixis, Inc. maintient ses prévisions de bénéfices pour l'année fiscale 2022
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
ETFs positioned on EXELIXIS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Genomics Immunology and Healthcare ...4.26%0.30%World
First Trust NYSE Arca Biotechnology Index F...4.16%0.70%United_States
First Trust NYSE Arca Biotechnology - Acc - USD3.37%3.84%-United_States
Invesco Dynamic Biotechnology & Genome ETF - USD3.06%3.11%United_States
VanEck Global Healthcare Leaders ETF - AUD2.11%1.47%-NC
More ETFs positioned on EXELIXIS, INC.
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 15,68 $
Average target price 26,85 $
Spread / Average Target 71,2%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-14.22%5 046
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044